MXPA02004071A - 2-(4,6-dimetil -pirimidin-2-iloxi) -3-(2-(3,4 -dimetoxifenil) etoxi) -3, 3-difenil propionato de sodio y su uso como antagonista de endotelina. - Google Patents

2-(4,6-dimetil -pirimidin-2-iloxi) -3-(2-(3,4 -dimetoxifenil) etoxi) -3, 3-difenil propionato de sodio y su uso como antagonista de endotelina.

Info

Publication number
MXPA02004071A
MXPA02004071A MXPA02004071A MXPA02004071A MXPA02004071A MX PA02004071 A MXPA02004071 A MX PA02004071A MX PA02004071 A MXPA02004071 A MX PA02004071A MX PA02004071 A MXPA02004071 A MX PA02004071A MX PA02004071 A MXPA02004071 A MX PA02004071A
Authority
MX
Mexico
Prior art keywords
compound
sodium
ethoxy
formula
endothelin antagonist
Prior art date
Application number
MXPA02004071A
Other languages
English (en)
Spanish (es)
Inventor
Jansen Rolf
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of MXPA02004071A publication Critical patent/MXPA02004071A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA02004071A 1999-10-27 2000-10-17 2-(4,6-dimetil -pirimidin-2-iloxi) -3-(2-(3,4 -dimetoxifenil) etoxi) -3, 3-difenil propionato de sodio y su uso como antagonista de endotelina. MXPA02004071A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19951671A DE19951671A1 (de) 1999-10-27 1999-10-27 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist
PCT/EP2000/010202 WO2001030767A1 (de) 1999-10-27 2000-10-17 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionsäure-natriumsalz und seine verwendung als endothelinantagonist

Publications (1)

Publication Number Publication Date
MXPA02004071A true MXPA02004071A (es) 2002-10-11

Family

ID=7927001

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02004071A MXPA02004071A (es) 1999-10-27 2000-10-17 2-(4,6-dimetil -pirimidin-2-iloxi) -3-(2-(3,4 -dimetoxifenil) etoxi) -3, 3-difenil propionato de sodio y su uso como antagonista de endotelina.

Country Status (17)

Country Link
EP (1) EP1228047A1 (de)
JP (1) JP2003512460A (de)
KR (1) KR20020047301A (de)
CN (1) CN1384822A (de)
AU (1) AU1272701A (de)
BG (1) BG106700A (de)
BR (1) BR0015112A (de)
CA (1) CA2389012A1 (de)
CZ (1) CZ20021485A3 (de)
DE (1) DE19951671A1 (de)
HU (1) HUP0203476A3 (de)
IL (1) IL149312A0 (de)
MX (1) MXPA02004071A (de)
NO (1) NO20021986D0 (de)
SK (1) SK5962002A3 (de)
TR (1) TR200201169T2 (de)
WO (1) WO2001030767A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2656017T3 (es) 2004-06-24 2018-02-22 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de unión a ATP

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten

Also Published As

Publication number Publication date
BG106700A (en) 2003-02-28
AU1272701A (en) 2001-05-08
CA2389012A1 (en) 2001-05-03
CN1384822A (zh) 2002-12-11
NO20021986L (no) 2002-04-26
HUP0203476A2 (en) 2003-05-28
SK5962002A3 (en) 2002-09-10
KR20020047301A (ko) 2002-06-21
IL149312A0 (en) 2002-11-10
DE19951671A1 (de) 2001-05-03
BR0015112A (pt) 2002-10-29
CZ20021485A3 (cs) 2003-06-18
TR200201169T2 (tr) 2002-09-23
WO2001030767A1 (de) 2001-05-03
JP2003512460A (ja) 2003-04-02
HUP0203476A3 (en) 2003-07-28
EP1228047A1 (de) 2002-08-07
NO20021986D0 (no) 2002-04-26

Similar Documents

Publication Publication Date Title
US11584735B2 (en) Solid forms of a plasma kallikrein inhibitor and salts thereof
US20060173183A1 (en) Multicyclic bis-amide MMP inhibitors
TW575569B (en) Diazepan derivatives or salts thereof
WO2003053926A1 (fr) Nouveau derive de phenylalanine
JP2002504916A (ja) 抗転移及び抗腫瘍活性を有するバルビツール酸誘導体
US8044208B2 (en) Imidazole derivatives as inhibitors of TAFIa
MX2007004297A (es) Antagonistas no peptidicos de bradiquinina y composiciones farmaceuticas de los mismos.
FR2883285A1 (fr) Sel besylate de la 7-(2-(4-(3-trifluoromethyl-phenyl) -1,2,3,6-tetrahudro-pyrid-1-yl)ethyl) isoquinoleine, sa preparation et son utilisation en therapeutique
AU2007327959B2 (en) Urea and sulfamide derivatives as tafia inhibitors
US20050043304A1 (en) Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same
UA62923C2 (en) Thiol derivatives having an inhibiting activity relative to metal-peptidases, a pharmaceutical composition and a method for the treatment of cardiovascular diseases
HUT56074A (en) Process for producing acridine derivatives and pharmaceutical compositions comprising such compounds
NO20091106L (no) Tartratderivater for anvendelse som koaguleringsfaktor IXa inhibitorer
MXPA02004071A (es) 2-(4,6-dimetil -pirimidin-2-iloxi) -3-(2-(3,4 -dimetoxifenil) etoxi) -3, 3-difenil propionato de sodio y su uso como antagonista de endotelina.
AU679361B2 (en) Pyrimidine derivatives and pharmaceutical composition
US6306886B1 (en) Crystalline roxifiban
JPH0317078A (ja) ８‐置換４‐（ヘテロサイクリルメチルアミノ）‐キノリン
CN116018337A (zh) 铜绿假单胞菌毒力因子LasB抑制剂
EP0718290A1 (de) Heterocyclische Carboxyalkylderivate
US6469056B1 (en) Pharmaceutically active compounds, their preparation and use as ECE-inhibitors
JP2007506690A (ja) マトリックスメタロプロテイナーゼの阻害剤として使用される二環式イミノ酸誘導体
JPH11508588A (ja) キナゾリン誘導体
KR0181215B1 (ko) N-치환 헤테로 화합물 및 이의 제조방법
JP2800939B2 (ja) 三環式化合物、そのエステルおよびその塩
JPS61137869A (ja) ピペラジン誘導体